In Brief: Expanded Heart Failure Indication for Empagliflozin (Jardiance)

Date: April 18, 2022 Issue #:  1648Summary:  The sodium-glucose cotransporter 2 (SGLT2) inhibitor empagliflozin (Jardiance– Boehringer Ingelheim) was approved by the FDA in 2021 to reduce the risk of hospitalization for heart failure (HF) and cardiovascular death in patients with heart failure with reduced ejection fraction (HFrEF; LVEF ≤40%), regardless of whether or not they have type 2 diabetes. The indication h as now been expanded to include patients with HF with any ejection fraction. Empagliflozin is the first SGLT2 inhibitor to be approved in the US for this indication.
Source: The Medical Letter - Category: Drugs & Pharmacology Authors: Tags: canagliflozin dapagliflozin empagliflozin ertugliflozin Farxiga Forxiga Heart Failure Invokana Jardiance Steglatro type 2 diabetes Source Type: research